Business Context and Reporting Period
This Form 8-K Current Report, dated July 3, 2026, details a material definitive agreement entered into by Clarivate Plc (the "Company"). The filing announces the sale of the Company's Life Sciences and Healthcare business to an affiliate of Altaris, LLC (the "Buyer"). The transaction is expected to close by the end of calendar year 2026, subject to regulatory approvals and customary closing conditions.
Key Financial Metrics and Transaction Terms
The aggregate purchase price for the Life Sciences and Healthcare business is $600,000,000, structured as follows:
- Cash Consideration: $500,000,000 payable at closing, subject to customary adjustments for cash, indebtedness, working capital, and transaction expenses.
- Deferred Consideration: $25,000,000 payable no later than January 31, 2028, contingent on the completion of transition services.
- Debt Instrument: An unsecured senior note with a principal amount of $75,000,000 issued by a Buyer affiliate to a Clarivate subsidiary at closing.
The filing does not provide specific revenue, profit, or cash flow metrics for the Company or the divested business for the reporting period. The Buyer has secured equity and debt financing commitments to fund the transaction.
Material Changes and Executive Compensation
On July 3, 2026, Clarivate entered into a retention agreement with Henry Levy, President of Life Sciences & Healthcare, to ensure his commitment through the transaction's completion. Key terms include:
- Acceleration: Full vesting of unvested restricted stock units if the transaction closes prior to March 31, 2027.
- Forfeiture: Cancellation of unvested performance share units upon closing for no consideration.
- Severance: If Mr. Levy is terminated without cause within six months of closing, he is eligible for 18 months of base salary and target bonus, a 2026 annual bonus (if unpaid), and 18 months of COBRA premiums.
Outlook, Risks, and Contingencies
The transaction is subject to several material contingencies and risks:
- Closing Conditions: Requires regulatory approvals and satisfaction of representations and warranties. Shareholder approval is not required.
- Termination Rights: Either party may terminate if the transaction is not consummated by March 3, 2027, or if a final order makes the transaction illegal. A termination fee of $33,000,000 is payable by the Buyer in certain circumstances, guaranteed by the Altaris Funds.
- Forward-Looking Statements: Management anticipates cost savings and strategic benefits but notes risks related to global macroeconomic uncertainty, AI impacts, and the successful execution of the divestiture.
Investor Verification Checklist
- Verify the final closing date and whether all regulatory approvals have been obtained.
- Confirm the final purchase price after customary adjustments for cash, debt, and working capital.
- Review the transition services agreement to understand the timeline and scope of post-closing support.
- Monitor the status of the Buyer's financing commitments and the guarantee of the $33,000,000 termination fee.
- Assess the impact of the divestiture on Clarivate's remaining revenue streams and future financial guidance.